Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Provided By GlobeNewswire
Last update: Jul 14, 2025
July 14, 2025
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in
Familial Adenomatous Polyposis (FAP)
Read more at globenewswire.comNASDAQ:BDRX (11/7/2025, 8:00:02 PM)
5.4
+0.11 (+2.08%)
Find more stocks in the Stock Screener
